Research Frontiers reported a third-quarter loss of $0.01 per share, matching the year-earlier loss and producing 0.0% earnings growth. Revenue fell 78.6% to $0.08 million. There was no consensus estimate, so this is not a beat-or-miss story. It is a story about whether the company can stay solvent and listed until its supply chain comes back. The quarter delivered real progress on that supply chain. It also confirmed that the financial recovery is arriving later than management signaled in August. That is the central tension.

The flat per-share comparison flatters the quarter. Fee income was $77,041, versus $359,444 a year ago, and the net loss widened to $510,304 from $298,508. Part of the decline came from a nonrecurring government-contract royalty in the 2025 period. The rest reflects the disruption of SPD emulsion and film production at Gauzy. Higher royalties from motorcycle helmets and ski goggles partly offset the drop, but only modestly. Total expenses fell to $595,162 from $663,388, a sign of cost discipline, but with revenue this low the operating loss still grew to $518,121.

The balance sheet is more concerning. The release notes that cash of roughly $645,000 was only $19,671 below year-end 2025. That comparison masks $1.375 million of equity and warrant proceeds raised during the year. Nine-month operating cash burn rose to $1.39 million from $863,000. On the call, management compared cash with roughly $1.28 million at March 31, which means about $635,000 was consumed over two quarters. Working capital is about $538,000 and shareholders' equity is $612,789. Reserves against royalty receivables also rose to $1.55 million.

The call showed a clear shift in tone and in the operating narrative. In August, management was walking through contingency plans. In November, it was reporting milestones that had been completed:

• Gauzy's court-approved Israeli settlement, addressing about $61 million of liabilities, became effective in September.
• Gauzy's roughly $7 million October financing closed.
• Payments are now flowing to restart emulsion production in Israel and film production in Germany.

The aerospace pipeline also expanded. A newly unveiled light jet's manufacturer prefers SPD windows, and preliminary agreements were signed the day before the call with a well-known North American aircraft manufacturer. Those additions sit on top of the two aircraft programs cited previously. In automotive, all four OEM programs (Mercedes, Ferrari, Cadillac and McLaren) remain intact, and Cadillac has quoted larger volumes aimed at SUVs beyond the Celestiq. The architectural retrofit licensee is planning a substantially expanded facility. Management also discussed a hybrid supply model in which Gauzy makes the emulsion and third parties coat it into film, which would partially ease single-source risk.

The timeline, however, moved the wrong way. In August, management expected film production to be running and volumes rising by year-end. Now it does not expect material royalty recovery until after the fourth quarter of 2026. That leaves bears with legitimate ammunition:

• **Liquidity:** Management flagged a possible small additional financing if receivables tied to French tribunal rulings slip past November or December.
• **Gauzy's finances:** About $1.638 million of Gauzy's $7 million financing is itself linked to French outcomes, and investor skepticism about Gauzy's capacity persists.
• **Single supplier:** The company still has no second film supplier in place.
• **Listing status:** Research Frontiers faces Nasdaq bid-price and market-value deficiencies. The automatic 180-day extension is unavailable, so a hearing request and compliance plan are required in December. Management says it still aims to avoid a reverse split.

The market has been treating the stock accordingly. Shares opened at $0.50 after the August report, and the call referenced a price of roughly $0.35 to $0.37. That places the stock well below both the post-August level and its $0.72 200-day moving average. Investors have plainly discounted the delayed recovery and the dilution and listing overhang. No sentiment reading was available to gauge whether expectations shifted around this report.

The bottom line is that Research Frontiers turned hoped-for supply-chain milestones into completed ones and added genuine aerospace and automotive opportunities. The quarter's financials, however, deteriorated sharply, and the payoff has been pushed beyond year-end. With roughly $645,000 in cash, a Nasdaq compliance deadline approaching, and recovery dependent on a financially fragile sole supplier and pending French court rulings, the investment case now hinges less on demand, which looks credible, than on whether the company can bridge the gap without further meaningful dilution.